Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,594 | $3,947 | $4,762 | $5,554 |
| - Cash | $225 | $75 | $74 | $95 |
| + Debt | $1,038 | $858 | $791 | $789 |
| Enterprise Value | $7,407 | $4,730 | $5,480 | $6,248 |
| Revenue | $2 | $67 | $2 | $17 |
| % Growth | -97.1% | 4,128.6% | -90.7% | – |
| Gross Profit | -$1 | $64 | -$98 | -$77 |
| % Margin | -38.4% | 96.6% | -6,223.1% | -453.1% |
| EBITDA | -$277 | -$108 | -$136 | -$125 |
| % Margin | -14,317% | -161.5% | -8,621.3% | -738.7% |
| Net Income | -$306 | -$134 | -$161 | -$150 |
| % Margin | -15,815% | -201.2% | -10,220.1% | -886.3% |
| EPS Diluted | -2.55 | -1.12 | -1.36 | -1.27 |
| % Growth | -127.7% | 17.6% | -7.1% | – |
| Operating Cash Flow | -$108 | -$128 | -$132 | -$66 |
| Capital Expenditures | -$9 | -$4 | -$6 | -$1 |
| Free Cash Flow | -$117 | -$132 | -$137 | -$67 |